Table 6.
Subgroup analysis of the period of second-line therapy on PFS by age.
| Characteristic | Age at second-line therapy | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ≤60 years (n=128) |
61 to 70 years (n=135) |
≥71 years (n=123) |
|||||||
| Overall Events (N) |
HR (95%CI) | p-value | Overall Events (N) |
HR (95%CI) | p-value | Overall Events (N) |
HR (95%CI) | p-value | |
| Period of second-line therapy | 0.3705 | 0.0355 | 0.3384 | ||||||
| 2002-2009 | 43(44) | 1 | 37(37) | 1 | 25(26) | 1 | |||
| 2010-2013 | 41(43) | 0.72 (0.45: 1.14) |
47(48) | 0.54 (0.34: 0.86) |
46(47) | 1.39 (0.82: 2.37) |
|||
| 2014-2017 | 38(41) | 0.81 (0.5: 1.32) |
45(50) | 0.7 (0.44: 1.11) |
45(50) | 1.47 (0.86: 2.53) |
|||
| Second-line therapy | 0.2375 | 0.6923 | 0.5099 | ||||||
| COMBINED | 47(49) | 1 | 54(54) | 1 | 40(42) | 1 | |||
| FOLFOX or FOLFIRI | 38(39) | 1.14 (0.73: 1.79) |
31(32) | 0.92 (0.58: 1.44) |
16(16) | 1.34 (0.73: 2.45) |
|||
| MONO | 37(40) | 1.47 (0.94: 2.31) |
44(49) | 0.9 (0.6: 1.35) |
60(65) | 1.07 (0.7: 1.62) |
|||
| Disease Status | 0.6658 | 0.1386 | 0.2677 | ||||||
| Locally Advanced | 30(30) | 1 | 22(24) | 1 | 30(31) | 1 | |||
| Metastatic | 92(98) | 0.90 (0.58: 1.4) |
107(111) | 1.13 (0.69: 1.85) |
86(92) | 1.22 (0.77: 1.95) |
|||
| Time in first-line therapy (months) | 122(128) | 1.00 (0.96: 1.03) |
0.7188 | 129(135) | 0.92 (0.89: 0.95) |
<0.0001 | 116(123) | 0.95 (0.92: 0.98) |
0.0005 |
COMBINED, includes the following combination regimens: Cisplatin + gemcitabine, GEMOX, Gemcitabine + capecitabine and Others; FOLFOX, 5-fluorouracil/leucovorin + oxaliplatin; FOLFIRI, 5-fluorouracil/leucovorin + irinotecan; MONO, includes the following agents administered as monotherapy: Gemcitabine or Fluoropyrimidine.
p-value: Likelihood Ratio test p-value.